| Status | Proposed |
| Process | STA 2018 |
| ID number | 1531 |
Provisional Schedule
| Committee meeting | 18 March 2020 |
| Expected publication | 10 June 2020 |
Project Team
| Project lead | Gemma Barnacle |
Email enquiries
- If you have any queries please email TACommF@nice.org.uk
| Evidence Review Group / Assessment Group | School of Health and Related Research (ScHARR), University of Sheffield |
Consultees
| Companies sponsors | Pfizer (tafamidis) |
| Others | Department of Health & Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Cardiomyopathy UK |
| Professional groups | British Cardiovascular Society |
| Royal College of Physicians |
Commentators
| Comparator companies | Accord Healthcare (furosemide) (confidentiality agreement not signed, not participating) |
| Advanz Pharma (furosemide) (confidentiality agreement not signed, not participating) | |
| Akcea Therapeutics UK (inotersen) | |
| Alnylam Pharmaceuticals (patisiran) (confidentiality agreement not signed, not participating) | |
| Aurobindo Pharma (furosemide) (confidentiality agreement not signed, not participating) | |
| Generics UK (bumetanide) (confidentiality agreement not signed, not participating) | |
| Hameln Pharmaceuticals (furosemide) (confidentiality agreement not signed, not participating) | |
| M & A Pharmachem (furosemide) (confidentiality agreement not signed, not participating) | |
| Orion Pharma (furosemide) (confidentiality agreement not signed, not participating) | |
| Pinewood Healthcare (furosemide) (confidentiality agreement not signed, not participating) | |
| Rosemont Pharmaceuticals (furosemide) (confidentiality agreement not signed, not participating) | |
| Sanofi (furosemide) (confidentiality agreement not signed, not participating) | |
| Thame Laboratories (furosemide) (confidentiality agreement not signed, not participating) | |
| Wockhardt UK (furosemide) (confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | National Amyloidosis Centre, at UCL |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 July 2019 | Invitation to participate |
| 15 July 2019 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of tafamidis for treating transthyretin amyloid cardiomyopathy. Consultees and commentators will be provided with details of the timelines when the appraisal starts in mid-July. The timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission. As a result, NICE cannot deliver on its commitment to publish guidance within 3 months of marketing authorisation for a product that was subject to the Early Access to Medicines Scheme (EAMS). |
| 12 March 2019 (14:00) | Scoping workshop (London) |
| 23 January 2019 - 20 February 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance